The CD38-directed monoclonal antibody daratumumab (Darzalex) has been listed by the TGA for the treatment of patients with refractory or relapsed multiple myeloma. The immunotherapy is the first in its class to receive a listing in Australia. It has been approved by the TGA for use: in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, ...
Immunotherapy for multiple myeloma gets TGA tick
19 Jul 2017